Emergent Expects Moving OTC Naloxone Directions On Package To Sway US FDA Advisory Panel

Based on results from its study for switch NDA, with primary endpoint of users’ success in administering naloxone nasal spray, Emergent changes which DFl panels include the directions. FDA will tell advisory committee the firm has no study data validating effectiveness of changes.